During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...
An expert discusses strategies for monitoring response to treatment, including observation, Epstein-Barr virus (EBV) titers, ...
Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and ...
A panelist discusses how a 48-year-old man with recurrent nasopharyngeal carcinoma (NPC) presents with nasal congestion, ...
Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...
An expert discusses how recent data on adjuvant anti–PD-1 trials highlight the significance of disease-free survival (DFS) ...
An expert discusses the treatment approach for recurrence in Case 1, evaluating the combination of toripalimab + gemcitabine/cisplatin for recurrent disease and considering the potential for ...
An expert discusses how advances in JAK V617F monitoring have improved the assessment of disease status and guided treatment decisions and how risk assessment tools have transformed the ability to ...
T-cell therapy could potentially be moved to earlier lines of treatment in relapsed/refractory multiple myeloma based on emerging trial data, improving outcomes through earlier intervention before ...
Scott Eggener, MD, gave a talk at the LUGPA annual meeting titled “Leveraging Cutting-Edge Technologies to Enhance Prostate Cancer Treatments.” ...
An expert discusses the use of toripalimab in the treatment of recurrent and metastatic nasopharyngeal carcinoma (NPC) through clinical case introductions.
An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback